Fibrin

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
fibrinogen alpha chain
Identifiers
Symbol FGA
Entrez 2243
HUGO 3661
OMIM 134820
RefSeq NM_000508
UniProt P02671
Other data
Locus Chr. 4 q28

WikiDoc Resources for

Fibrin

Articles

Most recent articles on Fibrin

Most cited articles on Fibrin

Review articles on Fibrin

Articles on Fibrin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fibrin

Images of Fibrin

Photos of Fibrin

Podcasts & MP3s on Fibrin

Videos on Fibrin

Evidence Based Medicine

Cochrane Collaboration on Fibrin

Bandolier on Fibrin

TRIP on Fibrin

Clinical Trials

Ongoing Trials on Fibrin at Clinical Trials.gov

Trial results on Fibrin

Clinical Trials on Fibrin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrin

NICE Guidance on Fibrin

NHS PRODIGY Guidance

FDA on Fibrin

CDC on Fibrin

Books

Books on Fibrin

News

Fibrin in the news

Be alerted to news on Fibrin

News trends on Fibrin

Commentary

Blogs on Fibrin

Definitions

Definitions of Fibrin

Patient Resources / Community

Patient resources on Fibrin

Discussion groups on Fibrin

Patient Handouts on Fibrin

Directions to Hospitals Treating Fibrin

Risk calculators and risk factors for Fibrin

Healthcare Provider Resources

Symptoms of Fibrin

Causes & Risk Factors for Fibrin

Diagnostic studies for Fibrin

Treatment of Fibrin

Continuing Medical Education (CME)

CME Programs on Fibrin

International

Fibrin en Espanol

Fibrin en Francais

Business

Fibrin in the Marketplace

Patents on Fibrin

Experimental / Informatics

List of terms related to Fibrin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Fibrin is a protein involved in the clotting of blood. It is a fibrillar protein that is polymerised to form a "mesh" that forms a hemostatic plug or clot (in conjunction with platelets) over a wound site.

Fibrin is made from its zymogen fibrinogen, a soluble plasma glycoprotein that is synthesised by the liver. Processes in the coagulation cascade activate the zymogen prothrombin to the serine protease thrombin, which is responsible for converting fibrinogen into fibrin. Fibrin is then cross linked by factor XIII to form a clot.

Physiology

Fibrinogen (also called factor I) is a 340 kDa glycoprotein synthesised in the liver hepatocytes and megakaryocytes, which normally has a concentration between 1.5 - 4.0 g/L (normally measured using the Clauss method) in blood plasma. Therefore the concentration in plasma is about 7 µM. In its natural form, fibrinogen is useful in forming bridges between platelets, by binding to their GpIIb/IIIa surface membrane proteins; though fibrinogen's major use is as a precursor to fibrin.

Fibrinogen, the principal protein of vertebrate blood clotting is an hexamer containing two sets of three different chains (α, β, and γ), linked to each other by disulfide bonds. The N-terminal sections of these three chains are evolutionary related and contain the cysteines that participate in the cross-linking of the chains. However, there is no similarity between the C-terminal part of the α chain and that of the β and γ chains. The C-terminal part of the β and γ chains forms a domain of about 270 amino-acid residues. As shown in the schematic representation this domain contains four conserved cysteines involved in two disulfide bonds. On the alpha and beta chains, there is a small peptide sequence (called a fibrinopeptide). It is these small peptides that prevent fibrinogen spontaneously forming polymers with itself.

  • Fibrinogen [3] beta and gamma chains C-terminal domain signature

Role in disease

Excessive generation of fibrin due to activation of the coagulation cascade leads to thrombosis, while ineffective generation predisposes to hemorrhage.

Dysfunction or disease of the liver can lead to a decrease in fibrinogen production or the production of abnormal fibrinogen molecules with reduced activity (dysfibrinogenaemia). Hereditary abnormalities of fibrinogen (the gene is carried on chromosome 4) are of both quantitative and qualitative in nature and include; afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia, and hypodysfibrinogenaemia.

Diagnostic use

Fibrinogen levels can be measured in venous blood. Normal levels are about 150-300 mg/dL. Higher levels are, amongst others, associated with cardiovascular disease (>460 mg/dL). It may be elevated in any form of inflammation, as it is an acute phase protein.

It is used in veterinary medicine as an inflammatory marker: in horses a level above the normal range of 1.0-4.0 g/L suggests some degree of systemic inflammatory response.

Low levels of fibrinogen can indicate a systemic activation of the clotting system, with consumption of clotting factors faster than synthesis. This excessive clotting factor consumption condition is known as Disseminated Intravascular Coagulation or "DIC." DIC can be difficult to diagnose, but a strong clue is low fibrinogen levels in the setting of prolonged clotting times (PT or PTT), in the context of acute critical illness such as sepsis or trauma.

See also

bg:Фибрин

cs:Fibrinogen de:Fibringl:Fibrina it:Fibrina nl:Fibrineom:Fibrinsl:Fibrin fi:Fibrinogeeni sv:Fibrin ta:நாரினி (புரதம்)


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools